2024
Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration
Anderson G, Cook E, Blakely R, Sutcliffe J, Veenstra-VanderWeele J. Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration. Journal Of Inflammation Research 2024, 17: 2169-2172. PMID: 38628604, PMCID: PMC11019386, DOI: 10.2147/jir.s456000.Peer-Reviewed Original ResearchPlatelet serotoninSerotonin valuesTrials of SSRIsSerotonin reuptake inhibitorsPlatelet serotonin transportersSerotonin reductionSSRI administrationSSRI treatmentReuptake inhibitorsSerotonin transporterMemory impairmentSerotonin levelsSSRIsSerotoninDepletion of plateletsPlasma serotoninPeripheral serotoninSequelae of COVID-19Viremia patientsCardiovascular sequelaeCirculating serotoninHyperaggregable stateTreatment of COVID-19Clinical trialsLong COVID
1998
Serotonin Transporter-Blocking Properties of Nefazodone Assessed by Measurement of Platelet Serotonin
Narayan M, Anderson G, Cellar J, Mallison R, Price L, Nelson J. Serotonin Transporter-Blocking Properties of Nefazodone Assessed by Measurement of Platelet Serotonin. Journal Of Clinical Psychopharmacology 1998, 18: 67-71.. PMID: 9472845, DOI: 10.1097/00004714-199802000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationBlood PlateletsCarrier ProteinsDepressive DisorderFemaleHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsMiddle AgedNerve Tissue ProteinsPiperazinesSelective Serotonin Reuptake InhibitorsSerotoninSerotonin Plasma Membrane Transport ProteinsTriazolesConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsHAM-D scoresHamilton Rating ScaleSerotonin type 2Nefazodone treatmentPretreatment plateletBaseline plateletSSRI treatmentReuptake inhibitorsUptake blockadeTherapeutic dosesPlatelet serotoninClinical dosesDepressed patientsMajor depressionTreatment groupsDepression scoresNefazodoneType 2Percent changeUptake inhibitionRating ScalePercent decreasePlatelets